Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.4% – Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price rose 2.4% during trading on Tuesday . The company traded as high as $8.09 and last traded at $8.09. Approximately 53,681 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 71,135 shares. The stock had previously closed at $7.90.

Wall Street Analysts Forecast Growth

GYRE has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. Finally, Jefferies Financial Group assumed coverage on Gyre Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $16.00 price target on the stock. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Trading Up 2.4%

The company has a market cap of $779.31 million, a PE ratio of 269.76 and a beta of 1.99. The firm’s 50-day simple moving average is $7.61 and its two-hundred day simple moving average is $7.65.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new stake in Gyre Therapeutics during the 3rd quarter valued at about $38,000. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the period. JPMorgan Chase & Co. boosted its position in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Gyre Therapeutics during the 3rd quarter worth approximately $111,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.